Dermavant Sciences, a Phase 3 biotech developing therapies for dermatological diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The London, United Kingdom-based company was founded in 2015 and plans to list on the Nasdaq under the symbol DRMT. Dermavant Sciences filed confidentially on December 20, 2018. Jefferies, SVB Leerink and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
